Literature DB >> 2146221

Effects of angiotensin converting enzyme inhibitors and of hydralazine on endothelial function in hypertensive rats.

M Clozel1, H Kuhn, F Hefti.   

Abstract

The function of the endothelium is impaired in hypertension. In spontaneously hypertensive rats (SHR), acetylcholine-induced relaxation is decreased and serotonin-induced constriction is increased. The goal of our study was to evaluate the effect of a long-term treatment with cilazapril, a new angiotensin converting enzyme inhibitor, or hydralazine, a vasodilator, on the endothelium-dependent responses in aorta of SHR. Wistar-Kyoto rats were used as normotensive reference. Isolated aortic rings with or without endothelium were suspended in organ chambers. The rings with intact endothelium were contracted with norepinephrine. Acetylcholine-induced relaxation was markedly enhanced by cilazapril treatment. The tension achieved at maximal relaxation was 8 +/- 4% of norepinephrine contraction in the cilazapril-treated SHR versus 55 +/- 5% in the untreated SHR (p less than 0.001). Hydralazine had no significant effect. The effect of serotonin was also markedly modified by cilazapril. In untreated SHR, serotonin induced the release of a vasoconstrictor substance by the endothelium as assessed by the ratio of maximal tension induced by serotonin in rings with endothelium over maximal tension in rings without endothelium, which was greater than 1. This ratio was reversed in cilazapril-treated SHR but not in hydralazine-treated SHR. Captopril had effects similar to cilazapril. Finally, evaluation of carotid arteries showed that cilazapril also prevented morphological changes of the intima in SHR (i.e., infiltration by mononuclear cells). We conclude that angiotensin converting enzyme inhibitors prevent the functional and morphological alterations in endothelium that are found in hypertension and speculate that this action might participate in their antihypertensive effect.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2146221     DOI: 10.1161/01.hyp.16.5.532

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  23 in total

1.  Effect of celiprolol therapy on arterial dilatation in experimental hypertension.

Authors:  J P Tolvanen; X Wu; M Kähönen; K Sallinen; H Mäkynen; A Pekki; I Pörsti
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

Review 2.  Inhibition of the renin angiotensin system: implications for the endothelium.

Authors:  Carmine Savoia; Ernesto L Schiffrin
Journal:  Curr Diab Rep       Date:  2006-08       Impact factor: 4.810

Review 3.  Endothelial dysfunction and hypertension.

Authors:  C J Ferro; D J Webb
Journal:  Drugs       Date:  1997       Impact factor: 9.546

Review 4.  Role of the renin-angiotensin system in the pathogenesis of intimal hyperplasia: therapeutic potential for prevention of vein graft failure?

Authors:  Michael J Osgood; David G Harrison; Kevin W Sexton; Kyle M Hocking; Igor V Voskresensky; Padmini Komalavilas; Joyce Cheung-Flynn; Raul J Guzman; Colleen M Brophy
Journal:  Ann Vasc Surg       Date:  2012-03-22       Impact factor: 1.466

5.  Chronic treatment with the angiotensin I converting enzyme inhibitor, perindopril, protects in vitro carbachol-induced vasorelaxation in a rat model of vascular calcium overload.

Authors:  D Henrion; J M Chillon; C Capdeville-Atkinson; M Vinceneux-Feugier; J Atkinson
Journal:  Br J Pharmacol       Date:  1991-12       Impact factor: 8.739

6.  Endothelium-derived bradykinin is responsible for the increase in calcium produced by angiotensin-converting enzyme inhibitors in human endothelial cells.

Authors:  R Busse; D Lamontagne
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-07       Impact factor: 3.000

Review 7.  Drug Treatment of Hypertension: Focus on Vascular Health.

Authors:  Alan C Cameron; Ninian N Lang; Rhian M Touyz
Journal:  Drugs       Date:  2016-10       Impact factor: 9.546

8.  Replacement of salt by a novel potassium- and magnesium-enriched salt alternative improves the cardiovascular effects of ramipril.

Authors:  E M Mervaala; I Paakkari; J Laakso; R Nevala; T M Teräväinen; F Fyhrquist; H Vapaatalo; H Karppanen
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

9.  Quinapril treatment and arterial smooth muscle responses in spontaneously hypertensive rats.

Authors:  P Arvola; H Ruskoaho; H Wuorela; A Pekki; H Vapaatalo; I Pörsti
Journal:  Br J Pharmacol       Date:  1993-04       Impact factor: 8.739

10.  Synergistic interaction between enalapril, L-arginine and tetrahydrobiopterin in smooth muscle cell apoptosis and aortic remodeling induction in SHR.

Authors:  Shant Der Sarkissian; Eve-Lyne Marchand; David Duguay; Denis deBlois
Journal:  Br J Pharmacol       Date:  2004-06-14       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.